Testosterone, Free and Total, Includes Sex Hormone-Binding Globulin (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)
0081056
Copy Utility
Copied!
Choose the Right Test
ARUP Consult® assists with test selection and interpretation
Recommendations when to order or not order the test. May include related or preferred tests.
Provides a calculated value for free testosterone concentration using total testosterone measured by mass spectrometry. May be used to evaluate hyperandrogenism in children and cisgender females, monitor testosterone-suppressing hormone therapies (eg, antiandrogens or estrogens), evaluate testosterone status in individuals with protein-binding abnormalities, or evaluate hypogonadism in cisgender males.
Mnemonic
Unique test identifier.
TESTOS F&T
Methodology
Process(es) used to perform the test.
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry/Electrochemiluminescent Immunoassay The concentration of free testosterone is derived from a mathematical expression based on the constant for the binding of testosterone to sex hormone binding globulin.
Performed
Days of the week the test is performed.
Sun-Sat
Reported
Expected turnaround time for a result, beginning when ARUP has received the specimen.
1-4 days
New York DOH Approval Status
Indicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect between 6-10 a.m.
Collect
Serum separator tube or green (sodium or lithium heparin).
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.8 mL)
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
EDTA plasma.
Remarks
Stability
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Test Number
Components
Reference Interval
Testosterone by Mass Spec
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks)
59-125
5-16
Premature (31-35 weeks)
37-198
5-22
Newborn
75-400
20-64
1-5 months
14-363
Less than 20
6-24 months
Less than 37
Less than 9
2-3 years
Less than 15
Less than 20
4-5 years
Less than 19
Less than 30
6-7 years
Less than 13
Less than 7
8-9 years
2-8
1-11
10-11 years
2-165
3-32
12-13 years
3-619
6-50
14-15 years
31-733
6-52
16-17 years
158-826
9-58
18-39 years
300-1080
9-55
40-59 years
300-890
9-55
60 years and older
300-720
5-32
Premenopausal (18 years and older)
Not Applicable
9-55
Postmenopausal
Not Applicable
5-32
Tanner Stage I
2-15
2-17
Tanner Stage II
3-303
5-40
Tanner Stage III
10-851
10-63
Tanner Stage IV-V
162-847
11-62
Testosterone, Free by Mass Spec
Age
Male (pg/mL)
Female (pg/mL)
1-6 years
Less than 0.6
Less than 0.6
7-9 years
0.1-0.9
0.6-1.8
10-11
0.1-6.3
0.1-3.5
12-13
0.5-98.0
0.9-6.8
14-15
3-138.0
1.2-7.5
16-17
38.0-173.0
1.2-9.9
18 years and older
47-244
Not Applicable
18-30
Not Applicable
0.8-7.4
31-40
Not Applicable
1.3-9.2
41-51
Not Applicable
1.1-5.8
Postmenopausal
Not Applicable
0.6-3.8
Tanner Stage I
Less than or equal to 3.7
Less than 2.2
Tanner Stage II
0.3-21
0.4-4.5
Tanner Stage III
1.0-98.0
1.3-7.5
Tanner Stage IV
35.0-169.0
1.1-15.5
Tanner Stage V
41.0-239.0
0.8-9.2
Sex Hormone Binding Globulin
Age
Male (nmol/L)
Female (nmol/L)
1-30 days
13-85
14-60
31-364 days
70-250
60-215
1-3 years
50-180
60-190
4-6 years
45-175
55-170
7-9 years
28-190
35-170
10-12 years
23-160
17-155
13-15 years
13-140
11-120
16-17 years
10-60
19-145
18-49 years
17-56
25-122
50 years and older
19-76
17-125
Tanner Stage I
26-186
30-173
Tanner Stage II
22-169
16-127
Tanner Stage III
13-104
12-98
Tanner Stage IV
11-60
14-151
Tanner Stage V
11-71
23-165
Interpretive Data
Background information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Free testosterone concentration is calculated using total testosterone (measured by mass spectrometry) and the binding constant of testosterone and sex hormone-binding globulin (SHBG).
For individuals on testosterone-suppressing hormone therapies (e.g., antiandrogens or estrogens), refer to cisgender female reference intervals. For a complete set of all established reference intervals, refer to ltd.aruplab.com/Tests/Pub/0081056.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Compliance Category
Laboratory Developed Test (LDT)
Note
Additional information related to the test.
Please refer to individual components for stability of sample for this test.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Other names that describe the test. Synonyms.
Testosterone Free
Testosterone, Free and Total, Includes Sex Hormone-Binding Globulin (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)
Chat
Feedback
